Dynavax to Present Data on Toll-like Receptor 9 Agonist SD-101 at the ASCO Annual Meeting 2019
April 18 2019 - 4:05PM
Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated
biopharmaceutical company focused on discovering and developing
novel vaccines and immuno-oncology therapeutics, today announced it
will present data from a Phase 1b/2 combination study of SD-101 and
pembrolizumab for patients with advanced melanoma and for patients
with recurrent or metastatic head and neck squamous cell carcinoma,
at the 2019 American Society of Clinical Oncology (ASCO) Annual
Meeting being held May 31 – June 4 in Chicago.
Abstract Number and Title: #6039, “Phase 1b/2,
open label, multicenter study of intratumoral SD-101 in combination
with pembrolizumab in anti-PD-1 treatment naive patients with
recurrent or metastatic head and neck squamous cell carcinoma
(HNSCC)”Poster Session Title: Head and Neck Cancer
Session Date and Time: Sat, Jun 01, 1:15 PM - 4:15
PMSession Location: McCormick Place, Exhibit Hall
A, Poster Board Number: #28
Abstract Number and Title: #9534, “Phase 1b/2,
open label, multicenter, study of the combination of SD-101 and
pembrolizumab in patients with advanced melanoma who are naïve to
anti-PD-1 therapy”Poster Session Title:
Melanoma/Skin CancersSession Date and Time: Mon,
Jun 03, 1:15 PM - 4:15 PMSession Location:
McCormick Place, Exhibit Hall A, Poster Board Number: #105
Abstract Number and Title: #9555, “Phase 1b/2,
open label, multicenter, study of the combination of SD-101 and
pembrolizumab in patients with advanced/metastatic melanoma
resistant to anti-PD-1/PD-L1 therapy”Poster Session
Title: Melanoma/Skin CancersSession Date and
Time: Mon, Jun 03, 1:15 PM - 4:15 PMSession
Location: McCormick Place, Exhibit Hall A, Poster Board
Number: #126
About SD-101 SD-101, the Company's lead
clinical candidate, is a proprietary, second-generation, Toll-like
receptor 9 (TLR9) agonist CpG-C class
oligodeoxynucleotide. Dynavax is evaluating this
intratumoral TLR9 agonist in several clinical studies to assess its
safety and activity, including a Phase 1b/2 study in combination
with KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy, in
patients with advanced melanoma and in patients with head and neck
squamous cell cancer, in a clinical collaboration with
Merck. Dynavax maintains all commercial rights to
SD-101.
About Dynavax Dynavax is a
fully-integrated biopharmaceutical company focused on leveraging
the power of the body's innate and adaptive immune responses
through toll-like receptor (TLR)
stimulation. Dynavax discovers and develops novel
vaccines and immuno-oncology therapeutics. The Company’s first
commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant),
Adjuvanted], is approved in the U.S. for prevention of infection
caused by all known subtypes of hepatitis B virus in adults age 18
years and older. Dynavax's lead immunotherapy product,
SD-101, is an investigational cancer immunotherapeutic currently
being evaluated in Phase 1/2 studies and its second cancer
immunotherapeutic, DV281, is in Phase 1 development. For more
information, visit www.dynavax.com.
ContactHeather Rowe Vice President, Investor
Relations & Corporate Communications 510-665-7269
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Apr 2023 to Apr 2024